GlassScriptPhysician profile
Randolph P Whitford
NPI 1144220104
$3,810.92
in general payments reported to CMS, 2019-2025
21 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $167 · 2021: $444 · 2022: $674 · 2023: $444 · 2024: $677 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $745.11 | 2019-2021 | |
| Abbvie INC. | $660.47 | 2022-2025 | Durysta, Lumigan |
| Oyster Point Pharma, INC. | $382.60 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $266.63 | 2023-2025 | Miebo, Scoutpro Osmolarity System |
| Sun Pharmaceutical Industries INC. | $261.29 | 2019-2025 | Cequa |
| Shire North American Group INC | $256.67 | 2019 | |
| Aerie Pharmaceuticals, INC. | $246.52 | 2019-2021 | |
| Harrow Eye, LLC | $169.93 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $141.01 | 2019-2022 | |
| Sight Sciences, INC. | $140.84 | 2024 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $121.86 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $78.88 | 2024 | |
| Novartis Pharmaceuticals Corporation | $69.69 | 2019-2021 | |
| Allergan, INC. | $64.67 | 2021 | |
| Dompe US, INC. | $64.17 | 2024 | Oxervate |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $35.79 | 2019-2020 | |
| Ocular Therapeutix, INC. | $24.62 | 2025 | Dextenza |
| Glaukos Corporation | $24.23 | 2021 | |
| Thea Pharma INC. | $20.60 | 2025 | Iyuzeh |
| Tearlab Corp | $20.34 | 2021 | |
| Alcon Vision LLC | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Whitford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.